Drug Approval | October 04, 2024
Shilpa Pharma Lifesciences receives CEP from EDQM for API, Desmopressin
This is used to treat central diabetes insipidus and bedwetting
This is used to treat central diabetes insipidus and bedwetting
Alcaftadine Ophthalmic Solution, 0.25% (OTC) is used to temporarily relieve itchy eyes due to pollen, ragweed, grass, animal hair, and dander
The Lilly Medicine Foundry is set to drive innovation in drug production and make medicines for clinical trials
Expansion includes a new 5-story, 136k sq. ft. multipurpose building in Sejong
The transaction involves the acquisition of 100% shareholding of Bharat Serums and Vaccines (BSV) by Mankind Pharma
This facility underwent an inspection from 15th to 19th July 2024 and has been classified as Voluntary Action Indicated
The product is expected to be launched in Q3FY25
Gilead Sciences first launched Lenacapavir under the brand name Sunlenca in the United States and Europe markets in the year 2022
Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun
The inspection conducted by EDQM at its Visakhapatnam facility
Subscribe To Our Newsletter & Stay Updated
